Journal of the American Society of Hypertension
Volume 1, Issue 2 , Pages 113-119 , March 2007

Inflammation in high blood pressure: a clinician perspective

  • Firas A. Ghanem, MD

      Affiliations

    • Dr. Ghanem has served on the speaker’s bureau for Novartis and Sankyo pharmaceuticals. There is no conflict of interest for Dr. Movahed.
    • ,
  • Assad Movahed, MD, FACP, FACC

      Affiliations

    • Dr. Ghanem has served on the speaker’s bureau for Novartis and Sankyo pharmaceuticals. There is no conflict of interest for Dr. Movahed.
    • Corresponding Author InformationCorresponding author: Assad Movahed, MD, FACP, FACC, The Brody School of Medicine, East Carolina University, Greenville, North Carolina 27834. Tel: 252-744-4651; fax: 252-744-5884.

Received 11 November 2006 ,Accepted 17 January 2007.

References 

  1. American Heart Association. Heart and stroke statistics: 2005 update. Dallas, Texas: American Heart Association; 2005;
  2. Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, et al. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT: Multiple Risk Factor Intervention Trial. Am Heart J. 1986;112:825–836
  3. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–126
  4. Dzau VJ. Theodore Cooper Memorial Lecture (Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis). Hypertension. 2001;37:1047–1052
  5. Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens. 2001;14:S83–S9
  6. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843
  7. Wang TJ, Larson MG, Levy D, Benjamin EJ, Kupka MJ, Manning WJ, et al. C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study. Circulation. 2002;106:1189–1191
  8. Luscher TF, Barton M. Biology of the endothelium. Clin Cardiol. 1997;20:II3–II10
  9. Verma S, Anderson TJ. The ten most commonly asked questions about endothelial function in cardiology. Cardiol Rev. 2001;9:250–252
  10. Gimbrone MA. Vascular endothelium: an integrator of pathophysiologic stimuli in atherosclerosis. Am J Cardiol. 1995;75:67B–70B
  11. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens. 2003;17:223–230
  12. Rizzoni D, Porteri E, Castellano M, Bettoni G, Muiesan ML, Tiberio G, et al. Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure. Hypertension. 1998;31:335–341
  13. Mervaala EM, Muller DN, Park JK, Schmidt F, Lohn M, Breu V, et al. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension. 1999;33:389–395
  14. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. J Am Med Assoc. 2003;290:2945–2951
  15. Niskanen L, Laaksonen DE, Nyyssonen K, Punnonen K, Valkonen VP, Fuentes R, et al. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension. 2004;44:859–865
  16. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: the ATTICA Study. Am J Hypertens. 2004;17:568–573
  17. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit. 2005;11:RA194–RA205
  18. de Groot AA, van Zwieten PA, Peters SL. Involvement of reactive oxygen species in angiotensin II-induced vasoconstriction. J Cardiovasc Pharmacol. 2004;43:154–159
  19. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?. Hypertension. 2004;44:248–252
  20. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders?. J Hypertens. 2003;21:1787–1803
  21. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis?. Hypertension. 2004;44:6–11
  22. Gonzalez AS, Guerrero DB, Soto MB, Diaz SP, Martinez-Olmos M, Vidal O. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. Eur J Clin Nutr. 2006;60:802–809
  23. Bullo M, Garcia-Lorda P, Megias I, Salas-Salvado J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res. 2003;11:525–531
  24. Allessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor-1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 1997;46:860–867
  25. Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I, et al. Association between blood pressure and fibrinolytic potential in the Framingham Offspring population. Circulation. 2000;101:264–269
  26. Stumpf C, John S, Jukic J, Yilmaz A, Raaz D, Schmieder RE, et al. Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens. 2005;23:995–1000
  27. Lip GY, Blann AD, Zarifis J, Beevers M, Lip PL, Beevers DG. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis? (A preliminary report). J Hypertens. 1995;13:1674–1678
  28. Blann AD, Tse W, Maxwell SJ, Waite MA. Increased levels of the soluble adhesion molecule E-selectin in essential hypertension. J Hypertens. 1994;12:925–928
  29. Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension?. J Hypertens. 2001;19:857–861
  30. Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens. 2003;16:429–433
  31. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension. 2001;38:399–403
  32. Schillaci G, Pirro M, Gemelli F, Pasqualini L, Vaudo G, Marchesi S, et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens. 2003;21:1841–1846
  33. Abramson JL, Weintraub WS, Vaccarino V. Association between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension. 2002;39:197–202
  34. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19:149–154
  35. Lakoski SG, Cushman M, Palmas W, Blumenthal R, D’Agostino RB, Herrington DM. The relationship between blood pressure and C-reactive protein in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 2005;46:1869–1874
  36. Lakoski SG, Herrington DM, Siscovick DM, Hulley SB. C-reactive protein concentration an incident hypertension in young adults. Arch Intern Med. 2006;166:345–349
  37. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–369
  38. Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev. 2006;24:33–50
  39. Pedrinelli R, Dell’Omo G, Di Bello V, Pellegrini G, Pucci L, Del Prato S, et al. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol. 2004;24:2414–2419
  40. Tsioufis C, Dimitriadis K, Chatzis D, Vasiliadou C, Tousoulis D, Papademetriou V, et al. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol. 2005;96:946–951
  41. Tsioufis C, Stougiannos P, Kakkavas A, Toutouza M, Mariolis A, Vlasseros I, et al. Relation of left ventricular concentric remodeling to levels of C-reactive protein and serum amyloid A in patients with essential hypertension. Am J Cardiol. 2005;96:252–256
  42. Spencer CG, Gurney D, Blann AD, Beevers DG, Lip GY ASCOT Steering Committee, Anglo-Scandinavian Cardiac Outcomes Trial. Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension. 2002;40:61–66
  43. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003;108:2993–2999
  44. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004;109(25 suppl 1):IV6–IV19
  45. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk in Communities Study. Arch Intern Med. 2006;166:1368–1373
  46. Ruilope LM, Malacco E, Khder Y, Kandra A, Bonner G, Heintz D. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther. 2005;27:578–587
  47. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol. 2004;43:2116–2123
  48. Julius S, Kjeldsen SE, Weber M VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:2022–2031
  49. Ridker PM, Danielson E, Rifai N, Glynn RJ Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension. 2006;48:73–79
  50. Chobanian AV, Bakris GL, Black HR, et al. National High Blood Pressure Education Program Coordinating Committee The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (The JNC 7 report). JAMA. 2003;289:3560–3572
  51. Ryu SY, Lee YS, Park J, Kang MG, Kim KS. Relations of plasma high-sensitivity C-reactive protein to various cardiovascular risk factors. J Korean Med Sci. 2005;20:379–383
  52. Ford ES. Does exercise reduce inflammation? (Physical activity and C-reactive protein among US adults). Epidemiology. 2002;13:561–568
  53. Aronson D, Sella R, Sheikh-Ahmad M, Kerner A, Avizohar O, Rispler S, et al. The association between cardiorespiratory fitness and C-reactive protein in subjects with the metabolic syndrome. J Am Coll Cardiol. 2004;44:2003–2007
  54. Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J Am Coll Cardiol. 2004;43:1056–1061
  55. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 2002;105:564–569
  56. Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J. 2005;26:1765–1773

PII: S1933-1711(07)00016-2

doi: 10.1016/j.jash.2007.01.004

Journal of the American Society of Hypertension
Volume 1, Issue 2 , Pages 113-119 , March 2007

Article Tools

* Image Usage & Resolution